Trial reportPharmacotherapy2026
Circulating Profiles of the Bile Acid Metabolomics in Patients With Polycystic Ovary Syndrome Treated With Metformin or Canagliflozin.
Trial report in Pharmacotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04700839 (The Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome: A Randomized, Open Label Trial
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveBile acids are indispensable modulators in the development of polycystic ovary syndrome (PCOS). Our previous study identified that metformin and canagliflozin have similar efficacy in patients with PCOS combined with insulin resistance (IR). However, the effect of metformin or canagliflozin on bile acid metabolism in patients with PCOS has not been elucidated. The objective of this study was to use targeted metabolomics technology to compare alterations of circulating bile acid metabolites in patients with PCOS before and after treatment with metformin or canagliflozin. DESIGN AND PATIENTS: This study was a subanalysis of a previous randomized open-label study, in which patients with PCOS combined with IR were enrolled and treated with either metformin (n = 35) or canagliflozin (n = 33) for 12 weeks. MEASUREMENTS: The serum bile acid profile was measured using high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS). The differences in serum bile acid metabolites in patients with PCOS before and after treatment were analyzed. In addition, the correlation between bile acid metabolites and PCOS-related clinical characteristics was evaluated.
resultsThere were no significant differences in serum bile acid metabolites in patients with PCOS before and after canagliflozin treatment. Metformin treatment substantially decreased serum total bile acid levels in patients with PCOS, especially primary conjugated bile acids. The levels of taurochenodeoxycholic acid (TCDCA), glycocholic acid (GCA), and glycochenodeoxycholic acid (GCDCA) showed significant differences from baseline in the serum of patients with PCOS after treatment with metformin. Correlation analysis showed that alterations of GCA, TCDCA, and GCDCA were associated with changes in multiple clinical parameters of patients with PCOS treated with metformin.
conclusionThe effects of metformin and canagliflozin on bile acids metabolism in patients with PCOS are different. The beneficial effects of metformin on PCOS may be related to the changes in bile acid metabolites.
trial registrationClinicalTrials.gov: NCT04700839.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.